Table 1.
FDA recommendations and Pharmacokinetics of PPIs
| PPI | Brand Name | FDA-Approved Doses in Hypergastrinemic Hypersecretory States | IV Doses in Hypergastrinemic States | Bioavailability (%) | Time to peak Conc (hours) | Half-life (hours) |
|---|---|---|---|---|---|---|
| Omeprazole | Prilosec | 60 mg PO daily (starting dose) * Up to 120 mg PO TID has been administered |
30-40 | 0.5–3.5 | 0.5–3.0 | |
| Lansoprazole | Prevacid | 60 mg PO daily * Up to 180 mg PO daily has been administered |
80 | 1.5–3.0 | 0.5–2.5 | |
| Esomeprazole | Nexium | 40 mg PO BID * Up to 240 mg per day has been administered |
80 mg IV BID | 64-90 | 1.5–2.0 | 1.0–2.5 |
| Pantoprazole | Protonix | 40 mg PO BID or 80 mg IV BID for 7-10d * Up to 240 mg per day has been administered |
40 mg IV BID | 77 | 2.0–2.5 | 1.0 |
| Rabeprazole | Aciphex | 60 mg PO daily * Up to 100 mg daily or 60 mg PO BID have been administered |
52 | 2.0–5.0 | 1.0–2.0 |
Conc = concentration.